402958-97-8

Usage

Uses

Used in Pharmaceutical Industry:
Cyclopenta[c]pyrrole-1-carboxylic acid, (2S)-2-cyclohexyl-N-(pyrazinylcarbonyl)glycyl-3-Methyl-L-valyloctahydro-, ethyl ester, (1S,3aR,6aS)is used as a pharmaceutical intermediate for the development of novel therapeutic agents. Its complex structure and functional groups may offer unique binding properties and interactions with biological targets, making it a promising candidate for the creation of new drugs with specific mechanisms of action.
Used in Medicinal Chemistry Research:
In the realm of medicinal chemistry, Cyclopenta[c]pyrrole-1-carboxylic acid, (2S)-2-cyclohexyl-N-(pyrazinylcarbonyl)glycyl-3-Methyl-L-valyloctahydro-, ethyl ester, (1S,3aR,6aS)- serves as a key component in the synthesis of potential drug candidates. Its unique structural features and stereochemistry allow researchers to explore its potential in modulating biological pathways and developing new treatments for various diseases.
Used in Chemical Synthesis:
Cyclopenta[c]pyrrole-1-carboxylic acid, (2S)-2-cyclohexyl-N-(pyrazinylcarbonyl)glycyl-3-Methyl-L-valyloctahydro-, ethyl ester, (1S,3aR,6aS)-'s intricate structure makes it a valuable building block in organic synthesis, particularly for the creation of complex organic molecules with potential applications in various industries, including materials science, agrochemicals, and specialty chemicals.

Upstream product

• 402958-25-2 (1S,3aR,6aS)-ethyl octahydrocyclopenta[c]pyrrole-1-carboxylate 
• 402958-96-7 (S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoic acid 
• 98-97-5 2-pyrazylcarboxylic acid 
• 109183-71-3 N-(tert-butoxycarbonyl)-L-cyclohexylglycine 
• 402958-93-4 (S)-2-((S)-2-tert-Butoxycarbonylamino-2-cyclohexyl-acetylamino)-3,3-dimethyl-butyric acid methyl ester 
• 1147103-42-1 (1S,3aR,6aS)-ethyl octahydrocyclopenta[c]pyrrole-1-carboxylate hydrochloride 

Downstream Products

• 402959-36-8 (1S,3aR,6aS)-2-[(2S)-2-[[(2S)-2-cyclohexyl-2-[(2-pyrazinylcarbonyl)amino] acetyl]amino]-3,3-dimethylbutanoyl]-N-[(1S)-1-[(cyclopropylamino)(hydroxy)acetyl]butyl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide 
• 402957-28-2 (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide 
• 402958-99-0 (1S,3aR,6aS)-2-((S)-2-{(S)-2-Cyclohexyl-2-[(pyrazine-2-carbonyl)-amino]-acetylamino}-3,3-dimethyl-butyryl)-octahydro-cyclopenta[c]pyrrole-1-carboxylic acid [1-(cyclopropylcarbamoyl-hydroxy-methyl)-butyl]-amide 
• 402958-98-9 (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)octahydrocyclopenta[c]pyrrole-1-carboxylic acid 

Relevant academic research and scientific papers

PROCESS FOR THE SYNTHESIS OF TELAPREVIR, OR PHARMACEUTICALLY ACCEPTABLE SALTS OR SOLVATES AS WELL AS INTERMEDIATE PRODUCTS THEREOF

The invention relates to a process for the preparation of telaprevir, or a pharmaceutically acceptable salt or solvate thereof, wherein the process requires a smaller number of process steps and/or does not require the use of toxic and instable compounds compared to the known processes. Another embodiment refers to telaprevir, or a pharmaceutically acceptable salt or solvate thereof as well as to intermediate products for preparation of the same, wherein the afore-mentioned products are obtained by the process described herein.

P4 and P1′ optimization of bicycloproline P2 bearing tetrapeptidyl α-ketoamides as HCV protease inhibitors

We describe herein the design, synthesis, and antiviral activity of a series of P4 modified tetrapeptidyl α-ketoamides as HCV protease inhibitors. The most promising analog identified through this SAR, 5a, 5c, and 5e demonstrated excellent enzyme inhibitory potency, enzyme selectivity, cellular activity, and acceptable therapeutic indexes. With the aim of improving HCV protease inhibitors reported in our previous manuscripts, we synthesized and evaluated a series of 1a-based tetrapeptidyl α-ketoamides with additional P4 modification. The promising analog discovered through this SAR, 5a, was further derivatized at P1′ or P1 position. As a result of these efforts, we found that replacement of the P4 valine as seen in 1a with cyclohexylglycine (Chg) resulted in the discovery of 5a, 5c, and 5e endowed with improved cellular activity in comparison to 1a.